CN112007092A - Anti-alcohol composition and preparation method thereof - Google Patents
Anti-alcohol composition and preparation method thereof Download PDFInfo
- Publication number
- CN112007092A CN112007092A CN202011053587.4A CN202011053587A CN112007092A CN 112007092 A CN112007092 A CN 112007092A CN 202011053587 A CN202011053587 A CN 202011053587A CN 112007092 A CN112007092 A CN 112007092A
- Authority
- CN
- China
- Prior art keywords
- composition
- percent
- alcohol
- ampelopsis grossedentata
- hovenia dulcis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 123
- 238000002360 preparation method Methods 0.000 title claims abstract description 60
- 230000002075 anti-alcohol Effects 0.000 title abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 67
- 206010019133 Hangover Diseases 0.000 claims abstract description 58
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 54
- 241001018563 Nekemias grossedentata Species 0.000 claims abstract description 54
- 244000010000 Hovenia dulcis Species 0.000 claims abstract description 49
- 235000008584 Hovenia dulcis Nutrition 0.000 claims abstract description 49
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 48
- 235000021282 Sterculia Nutrition 0.000 claims abstract description 43
- 229940059107 sterculia Drugs 0.000 claims abstract description 43
- 239000000463 material Substances 0.000 claims abstract description 38
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 24
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 24
- 239000011718 vitamin C Substances 0.000 claims abstract description 24
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 21
- 230000001154 acute effect Effects 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 239000007901 soft capsule Substances 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract 2
- 239000000284 extract Substances 0.000 claims description 75
- 241000934878 Sterculia Species 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 239000004376 Sucralose Substances 0.000 claims description 13
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 13
- 235000019408 sucralose Nutrition 0.000 claims description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- 235000012239 silicon dioxide Nutrition 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 244000018795 Prunus mume Species 0.000 claims description 6
- 235000011158 Prunus mume Nutrition 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- 241001412228 Scaphium lychnophorum Species 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 4
- 239000004408 titanium dioxide Substances 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229920003081 Povidone K 30 Polymers 0.000 claims description 2
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 235000010215 titanium dioxide Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 107
- 230000000694 effects Effects 0.000 abstract description 47
- 201000007930 alcohol dependence Diseases 0.000 abstract description 46
- 210000004185 liver Anatomy 0.000 abstract description 21
- 238000002474 experimental method Methods 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 11
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 240000001058 Sterculia urens Species 0.000 abstract 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 31
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 31
- 102000027484 GABAA receptors Human genes 0.000 description 29
- 108091008681 GABAA receptors Proteins 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
- 241000700159 Rattus Species 0.000 description 21
- 239000002994 raw material Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 210000000582 semen Anatomy 0.000 description 15
- 238000001694 spray drying Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 238000001035 drying Methods 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000001476 alcoholic effect Effects 0.000 description 10
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 229930003935 flavonoid Natural products 0.000 description 7
- 235000017173 flavonoids Nutrition 0.000 description 7
- 150000002215 flavonoids Chemical class 0.000 description 7
- 230000000971 hippocampal effect Effects 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000028527 righting reflex Effects 0.000 description 7
- 238000007873 sieving Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 125000003158 alcohol group Chemical group 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 241001571446 Scaphium scaphigerum Species 0.000 description 4
- 240000006365 Vitis vinifera Species 0.000 description 4
- 235000014787 Vitis vinifera Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 244000144730 Amygdalus persica Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000029650 alcohol withdrawal Diseases 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000013944 peach juice Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an anti-alcohol composition, which comprises the following components in percentage by weight: 10 to 60 percent of ampelopsis grossedentata leaves, 1 to 20 percent of hovenia dulcis thunb, 1 to 10 percent of dark plum fruit, 1 to 10 percent of boat-fruited sterculia seed, 0.1 to 1 percent of vitamin C and 25 to 60 percent of auxiliary materials. The invention also discloses a preparation method of the composition, application of the composition in preparing functional food for relieving alcoholism and application of the composition in preparing medicines for preventing acute and/or chronic alcoholism, and the composition can be prepared into tablets, granules, capsules, soft capsules, powder or oral liquid and other dosage forms. According to the invention, the new resource food and a plurality of medicinal and edible traditional Chinese medicinal materials are scientifically and reasonably compounded to prepare the functional food composition with good taste, and relevant experiments prove that the composition can obviously decompose the alcohol concentration in blood, reduce the alcohol absorption, improve the activity of an anti-inebriation enzyme, prevent the effects of anti-inebriation and liver protection and prevent hangover, and has a prevention effect on acute and/or chronic alcoholism.
Description
Technical Field
The invention relates to an anti-alcoholism composition and a preparation method thereof, belonging to the technical field of functional foods and pharmacy.
Background
Wine has a long history in China, and forms a wine culture, so that the wine can not help the happiness of relatives and businesses with much reward. However, when people are happy, the symptoms such as nausea, vomiting and emotional instability are caused by drunkenness, and coma and respiratory function are exhausted and die in severe cases.
Alcohol intake affects most organ systems, and alcohol metabolism disorders (AUDs) play a crucial role in the brain, as alcohol alters the balance between GABA (the major inhibitory neurotransmitter) and glutamate (the major excitatory neurotransmitter) in the brain, leading to toxic, sedative, anxiolytic, tonic, and addictive symptoms. GABAA receptor (GABAAR) -mediated inhibitory neurotransmitters are enhanced by the action of alcohol, and it has been reported that there is a direct effect on both presynaptic GABA release and enhancement of postsynaptic GABAARs cells. GABAARs formed by a family of subunits located postsynaptic or extrasynaptic membranes exhibit different sensitivities to alcohol, forming a regulated dynamic transport state between cell pools, and extrasynaptic GABAARs are sensitive to alcohol concentrations in the blood during social drinking. Changes in the levels of several GABAAR subunits caused by alcohol are accompanied by behavioral disorders such as loss of righting reflex (LORR).
In animal experiments, rats taken alcohol for a long period of time produced profound GABAAR plasticity, which plays a key role in alcohol withdrawal and dependence. After acute drinking, some GABAARs are rapidly down-regulated, producing physiological and pharmacological changes consistent with tolerance and withdrawal symptoms in vivo as GABAARs become plastic. Alcohol-induced behavioral changes and GABAAR plasticity can be used as a screen for drugs that improve AUDs.
About 95% of alcohol entering human body undergoes oxidative metabolism by liver enzyme system (mainly alcohol dehydrogenase and acetaldehyde dehydrogenase), and alcohol is oxidized into acetaldehyde in liver mainly under the catalysis of Alcohol Dehydrogenase (ADH) and then into acetic acid under the catalysis of acetaldehyde dehydrogenase (ALDH). Thus, ADH and ALDH are the most important enzymes in vivo to reduce alcohol concentration.
The antialcoholic product is a series of products which can decompose the alcohol concentration, enhance the activity of acetaldehyde dehydrogenase and the like after a human body ingests a large amount of alcohol, and can be generally divided into three types, namely chemical drugs, Chinese medicinal preparations and health-care functional foods. The chemical product and the Chinese medicinal preparation can cause metabolic burden on liver and kidney while relieving alcoholism, thereby causing different degrees of damage to human body. The functional food serving as a diet product for assisting in improving adverse reaction symptoms after drinking does not generate any toxic or side effect on a body, can also play a role in repairing and nourishing damaged liver cells, is safe and reliable, and is favored by more and more consumers.
At present, relatively few functional foods for relieving alcoholism sold in the market exist, the additive components are single, the effect is slow, the effects of quickly relieving alcoholism and relieving hangover cannot be achieved, and obvious side effects and the like exist after the foods are taken, so that the expectations and appeal of the public drinking people on the antialcoholic product cannot be met. The composition is constructed by screening various pure plant flavonoid raw materials, so that the components can be synergized and act together, and the alcohol removal is promoted by improving the activities of Alcohol Dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH), so that the alcoholic liver injury is improved, and the hangover is relieved.
Disclosure of Invention
One of the purposes of the invention is to provide an anti-alcoholism composition which has the effects of enhancing the activity of alcohol dehydrogenase in vivo, relieving alcoholism and protecting liver, relieving hangover, resisting acute alcoholic liver injury and preventing acute and chronic alcoholism;
the invention also aims to provide a preparation method of the anti-alcoholism composition.
Based on the above purpose, the invention firstly provides a composition, which is prepared from the following components in percentage by weight: 10 to 60 percent of ampelopsis grossedentata leaves, 1 to 20 percent of hovenia dulcis thunb, 1 to 10 percent of dark plum fruit, 1 to 10 percent of boat-fruited sterculia seed, 0.1 to 1 percent of vitamin C and 25 to 60 percent of auxiliary materials.
In the composition, Ampelopsis grossedentata leaf is a new resource food approved by the national health and wellness Commission, and can be used as a common food raw material. The ampelopsis grossedentata leaf extract contains rich flavonoids, can improve the activity of antialcoholic enzymes (alcohol dehydrogenase and acetaldehyde dehydrogenase) in the liver, effectively prolong the intoxication latency, shorten the sobering time, protect the liver, accelerate the rapid decomposition of ethanol metabolite acetaldehyde to become a nontoxic substance, reduce the damage to liver cells, improve the activity increase of serum lactate dehydrogenase caused by liver cell damage, thereby playing the role of protecting the liver, greatly reducing the damage of ethanol to the liver and rapidly recovering the normal state of the liver.
The raisin tree seed is a product with homology of medicine and food, the raisin tree seed is neutral and nontoxic and enters spleen and stomach channels, and related experimental results show that flavonoid substances in the raisin tree seed extract can resist the damage of alcohol to a central nervous system, show that the flavonoid substances can shorten the lethargy time of an acute alcoholism mouse, reduce the number of autonomous activities caused by excitation of the central nervous system due to small-amount drinking, improve the learning and memory capacity, effectively reduce the content of alcohol in blood and increase the activity of alcohol dehydrogenase in liver. In a word, the hovenia dulcis thunb extract can rapidly relieve acute alcoholism symptoms, promote the metabolism of alcohol in the liver by inhibiting the absorption of alcohol in the gastrointestinal tract, accelerate the decomposition of alcohol and play an effective role in relieving alcoholism and preventing drunkenness.
The dark plum is also called plum, has sour, astringent and neutral taste, and is a product of homology of medicine and food. The dark plum contains flavonoid substances and various organic acids, can improve the function of the liver, and has the effect of helping an organism to relieve alcoholism.
Boat-fruited sterculia seed is sweet in taste, cold in nature, enters lung and large intestine meridians and is a product with homology of medicine and food. The boat-fruited sterculia seed extract also contains abundant flavonoids, and has the effects of clearing heat, moistening lung, relieving sore throat, easing up voice, relaxing bowel and accelerating metabolism of a human body.
In a preferred embodiment of the invention, the composition comprises the following components in the following compatible proportion by weight percentage: 30 to 50 percent of ampelopsis grossedentata leaves, 1 to 10 percent of hovenia dulcis thunb, 1 to 5 percent of dark plum fruit, 1 to 5 percent of boat-fruited sterculia seed, 0.1 to 0.5 percent of vitamin C and 35 to 50 percent of auxiliary materials.
In a more preferred embodiment, the composition comprises the following components in the following compatible proportions by weight percent: 50% of ampelopsis grossedentata leaves, 5% of hovenia dulcis thunb, 2% of dark plum fruit, 2% of boat-fruited sterculia seed, 0.15% of vitamin C and 40.85% of auxiliary materials.
More preferably, the Ampelopsis grossedentata leaf in the composition is Ampelopsis grossedentata leaf powder or powdered extract of Ampelopsis grossedentata leaf, preferably powdered extract of Ampelopsis grossedentata leaf.
The semen Hoveniae in the composition for relieving hangover is semen Hoveniae powder or semen Hoveniae powder extract, preferably semen Hoveniae powder extract.
The fructus mume in the anti-hangover composition is fructus mume powder or fructus mume powder extract, preferably fructus mume powder extract.
The semen Scaphii Lychnophori in the composition for relieving alcoholic intoxication is semen Scaphii Lychnophori powder or semen Scaphii Lychnophori powder extract, preferably semen Scaphii Lychnophori powder extract.
In a preferred embodiment of the invention, the adjuvant in the composition is selected from one or more of lactose, microcrystalline cellulose, maltodextrin, isomaltooligosaccharide, fruit and vegetable powder, concentrated fruit and vegetable juice, magnesium stearate, silicon dioxide, titanium dioxide, beeswax, purified water, sucralose, essence, pigment, glycerol, povidone K30, and gelatin.
Secondly, the invention provides a preparation method of the composition, and the method comprises the step of mixing Ampelopsis grossedentata leaves, Hovenia dulcis seeds, dark plum fruits, scaphium scaphigerum and vitamin C according to a compatible proportion.
In a preferred embodiment of the present invention, the Ampelopsis grossedentata leaves, Hovenia dulcis, Prunus mume and Sterculia Lychophora are all processed into powders before mixing.
In the process for preparing powders, the following are the specific embodiments adopted by the present invention:
1) the preparation method of the ampelopsis grossedentata leaf powder comprises the following steps:
the method comprises the following steps: picking dried Ampelopsis grossedentata leaves, and screening to remove impurities;
step two: and (3) crushing the ampelopsis grossedentata leaves subjected to impurity removal in the step one by using a crusher under proper conditions, preferably, the proper crushing conditions of the ampelopsis grossedentata leaves are that the humidity is less than 30% and the temperature is less than 25 ℃, the mesh number of the crushed ampelopsis grossedentata leaves is 40-80 meshes, and the moisture is controlled to be less than 5%.
2) The preparation method of the hovenia dulcis thunb powder comprises the following steps:
the method comprises the following steps: taking fresh and mature fruits of hovenia dulcis thunb as a raw material, soaking and cleaning, and draining water, wherein preferably, the soaking and rinsing time of the hovenia dulcis thunb is 5-15 min;
step two: spreading the drained hovenia dulcis thunb in the step one on a tray of a drying machine for drying, preferably, the drying temperature of the hovenia dulcis thunb is 45-55 ℃, the humidity is 5-20%, and the drying time is 3-7 h;
step three: and (2) crushing the dried hovenia dulcis thunb in the step two, preferably, the crushing condition of the hovenia dulcis thunb is that the humidity is less than 30% and the temperature is less than 25 ℃, the mesh number of the crushed hovenia dulcis thunb powder is between 50 and 100 meshes, and the moisture is controlled to be less than 5%.
3) The preparation method of the dark plum powder comprises the following steps:
pulverizing oven-dried or naturally sun-dried mume fructus with a pulverizer, preferably, the mume fructus is pulverized under the conditions of humidity less than 30% and temperature less than 25 deg.C, and the pulverized mume fructus has a mesh size of 60-100 meshes and water content below 5%.
4) The preparation method of the boat-fruited sterculia seed powder comprises the following steps:
the method comprises the following steps: fresh mature fruits of boat-fruited sterculia seeds are taken as raw materials, soaked and cleaned, and then drained, and preferably, the soaking and rinsing time of the boat-fruited sterculia seeds is 5-15 min;
step two: spreading the drained boat-fruited sterculia seed in the step one on a tray of a drying machine for drying, preferably, the drying temperature of the boat-fruited sterculia seed is 45-55 ℃, the humidity is 5-20%, and the drying time is 3-7 h;
step three: and D, crushing the dried boat-fruited sterculia seed in the step two, preferably, the crushing condition of the boat-fruited sterculia seed is that the humidity is less than 30 percent and the temperature is less than 25 ℃, the mesh number of the crushed boat-fruited sterculia seed powder is between 50 and 100 meshes, and the moisture is controlled to be less than 5 percent.
In a more preferred embodiment of the present invention, the Ampelopsis grossedentata leaf, Hovenia dulcis seed, Prunus mume and Sterculia Lychophora are all processed into powder extracts before mixing.
In the method for preparing the powdery extract, the following are specific embodiments adopted in the present invention:
1) the preparation method of the ampelopsis grossedentata leaf powdery extract comprises the following steps:
the method comprises the following steps: picking dried Ampelopsis grossedentata leaves, and screening to remove impurities;
step two: crushing the ampelopsis grossedentata leaves subjected to impurity removal in the step one by using a crusher; preferably, the mesh number of the crushed Ampelopsis grossedentata is 40-80 meshes;
step three: weighing a certain amount of the crushed Ampelopsis grossedentata leaves obtained in the second step, adding ethanol for reflux extraction, extracting for three times, and then combining the filtrates; preferably, 5 times volume of ethanol is added into the Ampelopsis grossedentata leaves, and reflux extraction is carried out for 50 min;
step four: concentrating the combined filtrate in the third step under vacuum condition to obtain extract; preferably, the concentration condition of the ampelopsis grossedentata leaf extracting solution is 0.6-0.8 Mpa of vacuum degree;
step five: adding water into the leaching paste, and standing at normal temperature for crystallization; preferably, 7 times of water with the pH value less than 7 at normal temperature is added into the extract, and the mixture is placed for crystallization for 24 hours;
step six: skimming the upper layer floating black oily substance in the fifth step, filtering the lower light green precipitate, and drying;
step seven: completely dissolving the crude product in the sixth step by using pure water, adding activated carbon for decolorization, and then removing impurities to finally obtain a powdery substance, namely the ampelopsis grossedentata leaf extract; preferably, the crude product is dissolved in 18 to 20 times the amount of pure water having a pH of less than 7 and decolorized with 10% activated carbon.
2) Preparing a hovenia dulcis thunb powdery extract:
the method comprises the following steps: taking fresh and mature fruits of hovenia dulcis thunb as raw materials, and crushing the hovenia dulcis thunb properly by using a wall breaking machine;
step two: weighing a certain amount of the hovenia dulcis thunb crushed in the step one, taking alcohol as a solvent, extracting by a hot reflux extraction method for 2-4 times, and then combining filtrates; preferably, the hovenia dulcis thunb is extracted by 75% alcohol through hot reflux for 2 hours, the addition amount of the alcohol is 8 times, and the extraction times are 2-4 times;
step three: concentrating the filtrate in the second step under vacuum condition to obtain concentrated solution; preferably, the hovenia dulcis thunb extract is concentrated to the relative density of 1.1-1.5 g/cm under the vacuum degree of 0.6-0.8 Mpa3;
Step four: spray drying the concentrated solution in step three by using a centrifugal spray drying tower, and crushing into fine powder after drying to obtain the hovenia dulcis thunb extract; preferably, the air inlet temperature of the hovenia dulcis thunb is 150-180 ℃ and the air outlet temperature is 70-90 ℃ during spray drying, and the hovenia dulcis thunb is dried and crushed into 80-100 meshes of fine powder, and the water content is controlled to be below 5%.
3) Preparing a dark plum powder extract:
the method comprises the following steps: pulverizing oven-dried or naturally sun-dried mume fructus with pulverizer;
step two: weighing the dark plum powder in the step one, adding ethanol for reflux extraction, extracting for 1-2 times to obtain dark plum extract, mixing the dark plum extract, filtering while hot, centrifuging, collecting supernatant, and performing suction filtration to obtain a concentrated solution; preferably, the dark plum is added with 50-95% of ethanol by mass percent for reflux extraction, the mass volume (kg/L) ratio of the dark plum to the ethanol is 1: 5-1: 25, the dark plum and the ethanol are extracted in a water bath at 50-70 ℃ for 1-3 hours, and the extraction is carried out for 1-2 times;
step three: spray-drying the concentrated solution in the step two by adopting a centrifugal spray-drying tower, and crushing into fine powder after drying to obtain a dark plum extract; preferably, the air inlet temperature of the dark plum extract is 150-180 ℃ and the air outlet temperature is 70-90 ℃ during spray drying, and the dark plum extract is dried and crushed into 80-100 meshes of fine powder, wherein the water content is controlled to be below 5%.
4) Preparing the boat-fruited sterculia powder extract:
the method comprises the following steps: using fresh and mature fruits of boat-fruited sterculia seed as raw material, and crushing the boat-fruited sterculia seed by using a wall breaking machine;
step two: weighing a certain amount of the crushed boat-fruited sterculia seeds in the step one, taking alcohol as a solvent, and extracting by adopting a hot reflux extraction method. Extracting for 2-3 times, and mixing filtrates; preferably, the sterculia lychnophora is extracted by a hot reflux extraction method for 2 hours by using 75% alcohol as a solvent, the adding amount of the alcohol is 8 times, and the extraction times are 2-4 times;
step three: concentrating the boat-fruited sterculia seed extract in the second step to a certain relative density under vacuum condition to obtain a concentrated solution; preferably, the boat-fruited sterculia seed extracting solution is concentrated to the relative density of 1.1-1.5 g/cm under the vacuum degree of 0.6-0.8 Mpa3;
Step four: spray drying the concentrated solution in the third step by using a centrifugal spray drying tower, and crushing into fine powder after drying to obtain the boat-fruited sterculia seed extract; preferably, the air inlet temperature of the boat-fruited sterculia seed concentrated solution is 150-180 ℃ and the air outlet temperature is 70-90 ℃ during spray drying, and the boat-fruited sterculia seed concentrated solution is dried and crushed into 80-100 meshes of fine powder, and the water content is controlled to be below 5%.
The invention also provides application of the composition in preparing functional food for relieving alcoholism.
Finally, the invention provides the use of the above composition for the preparation of a medicament for the prevention of acute and/or chronic alcoholism.
In a preferred embodiment, the composition is prepared as a powder, a tablet, a granule, a capsule, a soft capsule, or an oral liquid.
Compared with the prior art, the invention has the beneficial effects that:
the invention scientifically and reasonably compounds and organically combines new resource food and traditional Chinese medicines with homology of medicine and food, and flavonoid substances in the raw materials supplement each other in efficacy and act together, thus having no toxic or side effect on human bodies. Relevant experiments prove that the composition can increase the activity of acetaldehyde dehydrogenase in vivo, promote the rapid decomposition of alcohol in vivo, rapidly relieve the effect of alcohol of a large number of people who take alcohol, protect the liver, improve acute alcoholic liver injury, improve alcoholism dependence, relieve hangover and play a role in preventing acute and chronic alcoholism. Has good application and development prospect in the anti-alcohol market and related fields. The composition can be made into various dosage forms, has stable product and is easy for industrial production.
Drawings
The following describes embodiments of the present invention in further detail with reference to the accompanying drawings.
FIG. 1 is a graph showing the change in ADH activity of experimental mice in application example 2, and shows that the anti-hangover composition of the present invention increases the ADH activity of alcoholic mice.
Fig. 2 is a graph showing the comparison of the righting reflex time of the experimental rats in application example 3, which shows that the hangover alleviating composition of the present invention has an obvious recovery of the LORR time of the acute alcoholism rats.
FIG. 3 is a graph showing the results of electrophoresis of GABAAR a1 and a4 subunits and representative protein expression in hippocampal tissues of rats tested in example 3, showing that alcoholism significantly reduced the expression of GABAAR a1 subunit in hippocampal tissues, while the expression of GABAAR a4 subunit was significantly increased.
Fig. 4 is a statistical result chart of efficacy verification experiments in a human body feeding trial test using the anti-hangover composition of example 4.
Fig. 5 is a graph comparing the GABAAR a1 subunit and the a4 subunit proteins in the hippocampal tissues of the experimental rat in example 3, which shows that alcoholism significantly reduces the expression of GABAAR a1 subunit in the hippocampal tissues, while the expression of GABAAR a4 subunit is significantly increased, and the anti-inebriation composition of the present invention can significantly reverse these changes.
Detailed Description
The present invention is further illustrated below with reference to specific examples, which are to be construed as merely illustrative, and not limitative of the remainder of the disclosure. It will be apparent to those skilled in the art that various changes and modifications may be made in the invention without departing from the spirit and scope of the invention as defined in the following claims.
Preparation of example 1
The anti-inebriation composition is powder, and the formula compatibility among the raw materials of the anti-inebriation composition is as follows (the weight percentage is shown in brackets): 1.5g (50%) of ampelopsis grossedentata leaves, 0.15g (5%) of hovenia dulcis thunb, 0.05g (1.67%) of dark plum fruits, 0.05g (1.67%) of scaphium scaphigerum, 0.0045g (0.15%) of vitamins and auxiliary material components: 0.006g of sucralose (0.2%), 1.2395g of isomaltooligosaccharide (41.32%) and a mass ratio of raw materials to auxiliary materials of 1: 0.7. Wherein the auxiliary materials comprise sucralose as a sweetening agent and isomaltooligosaccharide as a filling agent.
The preparation method of the powder of the anti-alcoholism composition is carried out according to the following scheme:
the first step is as follows: preparation of a Ampelopsis grossedentata leaf powdery extract (Sanyuan Longsheng Biotechnology Limited liability company, 30%), a hovenia dulcis thunb powdery extract (Sanyuan Longsheng Biotechnology Limited liability company, 10:1 ratio extract), a dark plum powdery extract (Sanyuan Longsheng Biotechnology Limited liability company, 10:1 ratio extract), a sterculia scaphigera powdery extract (Sanyuan Longsheng Biotechnology Limited liability company, 10:1 ratio extract):
1) preparing a powdery extract of Ampelopsis grossedentata leaves:
the method comprises the following steps: picking dried Ampelopsis grossedentata leaves, and screening to remove impurities;
step two: crushing Ampelopsis grossedentata leaves by a crusher, wherein the mesh number is controlled between 40 meshes and 80 meshes;
step three: weighing a certain amount of Ampelopsis grossedentata leaves, adding 5 times of ethanol, reflux-extracting for 50min, extracting for three times, and mixing filtrates;
step four: concentrating the ampelopsis grossedentata leaf extracting solution to be paste-like under the vacuum degree of 0.6-0.8 Mpa;
step five: adding 7 times of water with pH less than 7 at normal temperature according to the volume ratio of the extract to the water of 1:7, standing and crystallizing for 24 h;
step six: skimming off the upper layer floating black oily substance, suction filtering to obtain the lower light green precipitate, and drying;
step seven: and (3) dissolving the crude product by using 18-20 times of pure water with the pH value of less than 7, adding 10% of activated carbon for decolorization after the crude product is completely dissolved, and removing impurities to finally obtain a powdery substance.
2) Preparing a hovenia dulcis thunb powdery extract:
the method comprises the following steps: taking fresh and mature fruits of hovenia dulcis thunb as raw materials, and crushing the hovenia dulcis thunb properly by using a wall breaking machine;
step two: weighing a certain amount of crushed hovenia dulcis thunb, taking 75% alcohol as a solvent, adopting a hot reflux extraction method, extracting for 2 hours, adding 8 times of alcohol, extracting for 2-4 times, and combining filtrates;
step three: the raisin tree seed extract is concentrated under the vacuum degree of 0.6-0.8 Mpa until the relative density is 1.1-1.5 g/cm3Then obtaining concentrated solution;
step four: spray drying in a centrifugal spray drying tower at air inlet temperature of 150-180 deg.c and air outlet temperature of 70-90 deg.c, crushing into 80-100 mesh powder with water content below 5%.
3) Preparing a dark plum powder extract:
the method comprises the following steps: pulverizing dried or naturally sun-dried mume fructus with pulverizer
Step two: weighing dark plum powder, adding 50-95% by mass of ethanol for reflux extraction, extracting dark plum and ethanol in a water bath at 50-70 ℃ for 1-3 h for 1-2 times to obtain dark plum extract, combining the dark plum extracts, filtering while hot, centrifuging, collecting supernatant, and performing suction filtration;
step three: spray drying in a centrifugal spray drying tower at air inlet temperature of 150-180 deg.c and air outlet temperature of 70-90 deg.c, crushing into 80-100 mesh powder with water content below 5%.
4) Preparing the boat-fruited sterculia powder extract:
the method comprises the following steps: using fresh and mature fruits of boat-fruited sterculia seed as raw material, and crushing the boat-fruited sterculia seed by using a wall breaking machine;
step two: weighing a certain amount of crushed boat-fruited sterculia seeds, taking 75% alcohol as a solvent, adopting a hot reflux extraction method, extracting for 2 hours, adding 8 times of ethanol, extracting for 2-4 times, and combining filtrates;
step three: the extracting solution of boat-fruited sterculia seed is concentrated to the relative density of 1.1 to 1.5g/cm under the vacuum degree of 0.6 to 0.8Mpa3Then obtaining concentrated solution;
step four: spray drying in a centrifugal spray drying tower at air inlet temperature of 150-180 deg.c and air outlet temperature of 70-90 deg.c, crushing into 80-100 mesh powder with water content below 5%.
And secondly, mixing and sieving the powdered extract of Ampelopsis grossedentata leaves, the powdered extract of Hovenia dulcis, the powdered extract of smoked plum and the powdered extract of Sterculia Lychophora according to the formula amount with vitamin C and auxiliary materials according to the formula amount to obtain the powder of the anti-alcoholism composition.
The third step: and (4) sequentially sterilizing, layering, boxing and plastic packaging the hangover-alleviating composition powder prepared in the second step to obtain a finished product of the hangover-alleviating composition powder, namely the hangover-alleviating composition solid beverage.
Preparation of example 2
The anti-inebriation composition is powder, and the formula compatibility among the raw materials of the anti-inebriation composition is as follows: 1.2g (40%) of ampelopsis grossedentata leaves, 0.08g (2.67%) of hovenia dulcis thunb, 0.04g (1.33%) of dark plum fruits, 0.04g (1.33%) of boat-fruited sterculia seeds, 0.0035g (0.12%) of vitamin C and auxiliary material components: 0.004g of sucralose (0.13%), 1.6325g of isomaltooligosaccharide (54.48%) and a mass ratio of raw materials to auxiliary materials of 1: 1.2. Wherein the auxiliary materials comprise sucralose as a sweetening agent and isomaltooligosaccharide as a filling agent.
The preparation method of the powder of the anti-alcoholism composition is carried out according to the following scheme: sieving Ampelopsis grossedentata leaf powder extract, semen Hoveniae powder extract, mume fructus powder extract, semen Scaphii Lychnophori powder extract, vitamin C, sucralose and isomaltooligosaccharide, and mixing.
Preparation of example 3
The anti-alcoholism composition is in the form of granules, and the formula compatibility proportion of the raw materials is as follows: 1.5g (50%) of ampelopsis grossedentata leaves, 0.15g (5%) of hovenia dulcis thunb, 0.05g (1.67%) of dark plum fruits, 0.05g (1.67%) of boat-fruited sterculia seeds, 0.0045g (0.15%) of vitamin C and auxiliary material components: 0.006g (0.2%) of sucralose, 1.2395g (41.32%) of maltodextrin and 1:0.7 of raw and auxiliary materials in mass ratio. Wherein the auxiliary materials comprise sucralose as a sweetening agent and maltodextrin as an anticaking agent and a filling agent.
The preparation method of the antialcoholic composition granules comprises the following steps: the oral liquid is prepared from Ampelopsis grossedentata leaf powder extract, Hovenia dulcis Thunb powder extract, mume fructus powder extract, semen Scaphii Lychnophori powder extract, vitamin C, sucralose and maltodextrin by sieving, mixing, granulating, oven drying and sieving.
Preparation of example 4
The anti-alcoholism composition is an oral liquid, and the formula compatibility proportions of the raw materials are as follows: 1.5g (50%) of ampelopsis grossedentata leaves, 0.15g (5%) of hovenia dulcis thunb, 0.05g (1.67%) of dark plum fruits, 0.05g (1.67%) of boat-fruited sterculia seeds, 0.0045g (0.15%) of vitamin C and auxiliary material components: 0.006g (0.2%) of sucralose, 1.24g (41.3%) of juicy peach concentrated juice (Heilongjiang Shanghai Zhi green wild berry, LLC, 8 times of concentrated peach concentrated juice), and the mass ratio of the raw materials to the auxiliary materials is 1: 0.7. Wherein the auxiliary materials comprise sucralose as a sweetening agent and concentrated juicy peach juice as a flavoring agent.
The preparation method of the anti-alcoholism composition oral liquid comprises the following steps: dissolving Ampelopsis grossedentata leaf powder extract, semen Hoveniae powder extract, mume fructus powder extract, semen Scaphii Lychnophori powder extract, vitamin C and sucralose in 30mL of purified water, filtering, instantly sterilizing at high temperature, and cooling to obtain the final product.
Preparation of example 5
The anti-alcoholism composition is a tablet, and the formula compatibility proportion of the raw materials is as follows: 1.5g (50%) of ampelopsis grossedentata leaves, 0.15g (5%) of hovenia dulcis thunb, 0.05g (1.67%) of dark plum fruits, 0.05g (1.67%) of boat-fruited sterculia seeds, 0.0045g (0.15%) of vitamin C and auxiliary material components: 1.241g of lactose (41.3%), 0.003g of magnesium stearate (0.1%), 0.0015g of silicon dioxide (0.05%) and a mass ratio of raw materials to auxiliary materials of 1: 0.7. Wherein, in the auxiliary material components, lactose is used as a filling agent, magnesium stearate is used as a lubricating agent, and silicon dioxide is used as a glidant.
The preparation method of the anti-alcoholism composition tablet comprises the following steps: lactose, ampelopsis grossedentata leaf powder extract, hovenia dulcis thunb powder extract, dark plum fruit powder extract, sterculia scaphigera powder extract and vitamin C, sieving, mixing with formula amounts of auxiliary materials of lactose, magnesium stearate and silicon dioxide, and tabletting.
Preparation of example 6
The anti-alcoholism composition is a capsule, and the formula compatibility proportions of the raw materials are as follows: 1.5g (50%) of ampelopsis grossedentata leaves, 0.15g (5%) of hovenia dulcis thunb, 0.05g (1.67%) of dark plum fruits, 0.05g (1.67%) of boat-fruited sterculia seeds, 0.0045g (0.15%) of vitamin C and auxiliary material components: 0.0009g (0.3) of silicon dioxide, 0.06g (2) of titanium dioxide, 0.87g (29) of gelatin, 0.025g (8.3) of glycerol, 0.2896g (9.65) of purified water and 1:0.7 of raw and auxiliary materials in mass ratio. Wherein in the auxiliary material components, silicon dioxide is used as a glidant, titanium dioxide is used as an opacifier, gelatin is used as a shaping agent, glycerol is used as a plasticizer, and purified water is used as a dissolving agent.
The preparation method of the anti-alcoholism composition capsule comprises the following steps: the capsule is prepared by sieving powdered extract of Ampelopsis grossedentata leaf, powdered extract of Hovenia dulcis Thunb, powdered extract of Prunus mume, powdered extract of Sterculia Lychophora seed and vitamin C, mixing, and encapsulating.
Preparation of example 7
The preparation form of the composition is a soft capsule, and the compatibility proportion of the raw materials is as follows: 1.5g (50%) of ampelopsis grossedentata leaves, 0.15g (5%) of hovenia dulcis thunb, 0.05g (1.67%) of dark plum fruits, 0.05g (1.67%) of boat-fruited sterculia seeds, 0.0045g (0.15%) of vitamin C and auxiliary material components: 0.5g (16.67%) of gelatin, 0.25g (8.3%) of glycerol, 0.5g (16.67%) of purified water and a mass ratio of raw materials to auxiliary materials of 1: 0.7. Wherein gelatin is used as a plasticizer, glycerin is used as a plasticizer, and purified water is used as a dissolving agent.
The preparation method of the anti-alcoholism composition soft capsule comprises the following steps: sieving Ampelopsis grossedentata leaf powder extract, semen Hoveniae powder extract, mume fructus powder extract, semen Scaphii Lychnophori powder extract and vitamin C, mixing, making into capsule shell, and pressing.
Application example 1 taste evaluation test
In this embodiment, a taste verification experiment of the anti-hangover composition prepared in preparation example 1 is considered, and the specific test process is as follows:
the anti-hangover composition prepared in preparation example 1 was used for taste and sensory evaluation, 10 persons were randomly selected for testing, and the color, taste, smell and other indicators of the product were examined and evaluated comprehensively. The evaluation indexes and standards are as follows:
TABLE 1 test index and evaluation Standard
The test results were as follows:
TABLE 2 test results score summary
The taste evaluation and summary results and data analysis show that the anti-alcoholism medicine prepared by the invention has the characteristics of uniform color, pleasant flavor, saturated and rich taste, high overall acceptance of the public and certain market development prospect.
Application example 2 Effect of the antialcoholic composition on Alcohol Dehydrogenase (ADH) Activity
In this example, the effect of the anti-hangover compositions prepared in preparation examples 1 and 2 on alcohol dehydrogenase Activity (ADH) in animal models was examined, and the specific test procedures are as follows:
1. experimental Material
Male BALB/C mice (body weight 30-35g) were from experimental animal center of guangdong province (SPF grade, certificate No. 2005a047, 2006a059), gavage, edible alcohol, physiological saline, the anti-hangover composition of preparation example 1, ADH assay kit, and the like.
2. Grouping of laboratory animals
The chronic alcoholism mice were divided into 5 groups of 8 mice each. All animals were kept under controlled temperature and humidity conditions in a 12h/12h light/dark cycle with free access to food and water. Animal experiments were approved by the ethical committee for animal research at river-south university.
3. Experimental methods
(1) Chronic alcoholic mouse model
Alcohol (25%, v/v) was gavaged, 0.2mL/10g body weight, and 250mg and 500mg per kg body weight were administered for 30min before or after the treatment in the preparation of the anti-hangover composition of example 1 or 2, 1 time per day for 12 consecutive days. The body weight of the mice was monitored every two days. After the experiment, mice were sacrificed and livers were dissected for Alcohol Dehydrogenase (ADH) assay.
(2) ADH assay
After the chronic alcohol treatment was over, the mice were sacrificed and the liver was dissected on ice. Liver homogenates were homogenized manually in 2mL glass jars and centrifuged (X3000 g, Beckmann J2-21 centrifuge, Beckmann instruments, Germany) for 10 min. Supernatants were collected for ADH assay. The ADH determination kit is purchased from Nanjing, China to build a biological laboratory, and experiments are carried out according to the manufacturer instructions. The general procedure was to add Nicotinamide Adenine Dinucleotide (NAD) in oxidized form to the liver sample, the absorbance of the reaction mixture was recorded at 340nm, and ADH activity was calculated from the absorbance values and protein content. ADH activity was expressed in units of 1nmoL ADH per mg protein per minute at 37 deg.C (U/mg), i.e., 1U/mg.
4. Results of the experiment
Alcohol had a significant effect on mouse body weight, with the mean body weight of the saline group increasing from 20.7 ± 1.25g to 30.36 ± 2.06g, while the mean body weight of the alcohol + saline group decreased from 22.52 ± 0.43g to 18 ± 2.88g [ P ═ 0.007] (table 3). From day 4 to day 12, the animal body weights of the high-concentration anti-hangover composition + alcohol group of preparation example 1 and the low-concentration anti-hangover composition + alcohol group of preparation example 2 were significantly higher than those of the alcohol + physiological saline group [ P ═ 0.02] (table 3), and from table 3, it can be seen that the high-concentration anti-hangover composition of preparation example 1 and the low-concentration anti-hangover composition of preparation example 2 were dose-dependent on the weight loss effect of the alcoholic mice.
ADH activity was significantly decreased in alcoholic mice compared to normal mice [ P ═ 0.002 ]. The anti-hangover composition reversed the decrease in ADH activity in the liver of alcoholism mice in a dose-dependent manner (fig. 1), indicating that the anti-hangover composition could exert its anti-alcoholism effect by enhancing ADH activity. In fig. 1, 1: normal saline + normal saline, 2: alcohol + normal saline, 3: the low concentration anti-hangover composition + alcohol of preparation example 2, 4: the high concentration anti-hangover composition + alcohol of preparation example 1, 5: alcohol + the high concentration anti-hangover composition of preparation example 1, 6: the high concentration anti-hangover composition of example 1 + physiological saline was prepared. Preparation example 1 the high concentration anti-hangover composition is added with 1.5g of ampelopsis grossedentata leaves, 0.15g of hovenia dulcis thunb, 0.05g of dark plum, 0.05g of sterculia lychnophora, 0.0045g of vitamin C, 1.2455g of auxiliary materials, and 3.0g of the total. Wherein, 1.755g of main material is added, accounting for 58.5 percent; preparation example 2 the low concentration anti-hangover composition is added with 1.2g of ampelopsis grossedentata leaves, 0.08g of hovenia dulcis thunb, 0.04g of dark plum, 0.04g of sterculia lychnophora, 0.0035g of vitamin C, 1.6365g of auxiliary materials, and 3.0g of the total. Wherein, 1.364g of main material is added, accounting for 45.5 percent. The main material ratio of the high-concentration anti-inebriation composition in the preparation example 1 is 1.3 times of that of the low-concentration anti-inebriation composition in the preparation example 2.
ADH reduces alcohol concentration in the body and is one of the most important enzymes in alcohol metabolism in the human body. When ADH activity decreases, the alcohol concentration in blood increases, exacerbating alcohol damage to the brain, liver and other vital organs. The anti-hangover composition can improve ADH activity and prevent weight loss after chronic alcohol contact. The increased ADH activity may be responsible for the alcohol detoxification of hepatocytes by the anti-hangover composition. In addition to the antidotal effect, the anti-hangover composition also inhibits voluntary alcohol consumption in alcohol-preference rats.
TABLE 3 Effect of antialcoholic compositions on body weight in alcoholism mice
Packet details
1. Normal saline + normal saline;
2. alcohol + normal saline;
3. preparation example 2 low concentration anti-hangover composition + alcohol;
4. preparation example 1 high concentration anti-hangover composition + alcohol;
5. alcohol + high concentration anti-hangover composition of preparation example 1;
6. the high concentration anti-hangover composition + physiological saline in preparation example 1 was prepared.
Note: data are presented as mean ± standard deviation (n ═ 8). P <0.05 compared to "alcohol + saline" treatment group; p <0.05 compared to "saline + saline" treatment group P < 0.05.
Experiment for improving acute alcoholism by using anti-alcoholic composition in example 3
In this example, the improvement effect of the anti-hangover composition prepared in preparation example 1 on alcoholism rats was examined, and the specific test procedures were as follows:
1. experimental Material
Male Sprague-Dawley rats (body weight 300-.
2. Grouping of laboratory animals
The acute alcohol test rats were divided into 5 groups of 6 rats each. All animals were kept under controlled temperature and humidity conditions in a 12h/12h light/dark cycle with free access to food and water. Animal experiments were approved by the ethical committee for animal research at river-south university.
3. Experimental methods
(1) Acute alcoholic rat model
Before or 30min after the treatment of the anti-hangover composition of preparation example 1, 25% (v/v) alcohol was gavaged at a dose of 2mL per 100g of body weight. Preparation of the antialcoholic composition of example 1 was administered at 1mL/100g or 500mg per kg body weight, respectively. After two days of rest, the protective effect of the anti-hangover composition was evaluated by the righting reflex (LORR) test. Rats were sacrificed and rat brain hippocampal tissue was dissected using western blot for GABAAR subunit analysis.
(2) Righting Reflex (LORR) test
Two days after alcoholism and abstinence, all animals received intraperitoneal injections (30mg/kg body weight) of diazepam (Shanxi Xin Bao Yuan pharmaceuticals Co., Ltd.). LORR and righting reflex recovery were observed. After each injection, animals were placed in a supine position in cages with iron wire lids. LORR was recorded as the time when the animal failed to turn. The animal was left in a supine position until the righting reflex was restored. The recovery of righting reflex was defined as the time the animal was able to recover 3 times in 60 s. The time to recovery of positive reflex was recorded for each animal.
(3) Protein sample preparation and western blot analysis
Following the LORR experiment, rats were anesthetized and tissues were isolated. Individual hippocampal tissues were dissected from the brain of each rat on ice. The P2 membrane fraction was homogenized, centrifuged at low speed in 0.32M sucrose, and the supernatant centrifuged (X12000 g, Beckman J2-21 centrifuge, Beckman Instruments, Germany) for 20 min. The particles were resuspended and washed with 20 volumes of phosphate buffered saline (PBS, 150mM NaCl, 10mM Na2HPO4/NaH2PO4, pH 7.4). The final pellets were recast into five rolls and PBS and protein concentrations were determined using the Bradford assay kit (Bio-Rad Laboratories, USA). 40 pounds of protein per sample was separated by 10% SDS-polyacrylamide gel electrophoresis. The protein was then transferred to a polyvinylidene fluoride membrane. The blot was stained with anti-peptide a1 or a4 antibody (1:1000, Santa Cruz Biotechnology, USA), followed by either horseradish peroxidase-labeled rabbit anti-antibody (1:2000, Zymed laboratories, USA) or anti-goat IgG (1:5000, Vector laboratories, Canada). The bands were detected with DAB staining (Sigma, usa). Beta-actin antibody (1: 1000). The optical density measurement was performed using an image analysis system (densitometer, Rudolph, usa), and bands of different groups of the respective molecular weights of the subunits were analyzed and the values thereof were compared.
4. Results of the experiment
As shown in fig. 2, 1: normal saline and normal saline, 2 normal saline and anti-inebriation composition, 3 alcohol and normal saline, 4 alcohol and 5 alcohol and anti-inebriation composition. In acute alcoholism rats (alcohol + saline group), LORR induced by diazepam was significantly reduced [ P ═ 0.0003], and the duration of gavage administration was about 60min in normal rats (saline + saline group), whereas LORR in acute alcoholism rats was 9.8 ± 3.27min, which was significantly different from that in normal rats [ P ═ 0.0003 ]. The anti-hangover composition of preparation example 1 had no significant effect on LORR duration in normal rats. The anti-hangover composition prepared in preparation example 1 has an obvious recovery effect on LORR time of acute alcoholism rats, as shown in a column 4 in fig. 2, and a measured value is 53.83 ± 6.11min [ P ═ 0.001], and the result shows that the anti-hangover composition has a significant anxiolytic effect in a LORR test induced by diazepam. But the therapeutic effect of administering an anti-hangover composition after alcohol intake is poor (as shown in fig. 2, bar 5). These data indicate that the composition can prevent, but not alleviate, alcohol disorders.
Figure 3 shows that alcoholism significantly reduced the expression of GABAAR a1 subunit in hippocampal tissues, while expression of GABAAR a4 subunit was significantly elevated (B in figures 3 and 5). In fig. 3, 1: normal saline + normal saline; 2: normal saline + anti-hangover composition; 3: normal saline and alcohol; 4: the anti-alcoholism composition plus normal saline; 5: alcohol + physiological saline. Figure 5 is a graph of the effect of an anti-hangover composition on the changes in GABAAR a1 subunit and a4 subunit expression in an alcoholic rat model. (A) Changes in GABAAR a1 subunit expression; (B) changes in GABAAR a4 subunit expression were measured as mean values, where 1: normal saline and normal saline, 2 the normal saline and the antialcoholic composition, 3 the normal saline and the alcohol, 4 the antialcoholic composition and the alcohol, and 5 the alcohol and the antialcoholic composition. GABAARs are a major target of alcohol activity, and a single dose of alcoholism may result in altered GABAAR plasticity, such as increased transcription of a4 and a2 and decreased a1 subunit, with preferential insertion of newly formed a4 into the synapse. To study alcohol withdrawal and dependence in humans, we established a model of Chronic Intermittent Ethanol (CIE) intoxication in rats. CIE rats showed changes in GABAAR subunit composition and subcellular localization. The current research shows that the single-dose alcohol treatment increases the expression of GABAAR a4 subunit and reduces the expression of GABAAR a1 subunit, and by detecting the expressions of GABAAR subunits a1 and a4 by using western blot, the recovery effect of the anti-alcoholism composition on LORR is related to the change of the GABAAR subunits, namely the anti-alcoholism composition can obviously reverse the change, namely the expression of a1 subunit is up-regulated, and the expression of a4 subunit is down-regulated. This data is consistent with the effect of the anti-hangover composition on diazepam-induced LORR recovery.
Efficacy verification of human body feeding trial test applying the anti-hangover composition of example 4
In this embodiment, the efficacy of the anti-hangover composition prepared in preparation example 1 in a human body eating trial test is examined, and the specific test process is as follows:
the powders for preparing the anti-hangover composition prepared in example 1 were administered to 60 drinkers, respectively, and the physical characteristics and the proportion of anti-hangover effect of the anti-hangover composition prepared in example 1 were observed and recorded, with the results shown in fig. 4. In fig. 4, 48 of the test takers who took the anti-hangover composition in the human body test results fed back that the composition has a significant anti-hangover effect, accounting for 80%, which is significantly different from the test takers who fed back no effect (accounting for 20%), indicating that the anti-hangover composition of the present invention can increase the activity of acetaldehyde dehydrogenase in vivo, promote the rapid decomposition of alcohol in vivo, rapidly relieve the hangover of a large number of alcohol intakers, protect the liver, improve acute alcoholic liver injury, improve alcoholism dependency, relieve hangover, and play a role in preventing acute and chronic alcoholism.
Claims (10)
1. The composition is characterized by comprising the following components in percentage by weight:
10 to 60 percent of ampelopsis grossedentata leaves, 1 to 20 percent of hovenia dulcis thunb,
dark plum 1-10 wt%, boat-fruited sterculia seed 1-10 wt%,
0.1 to 1 percent of vitamin C and 25 to 60 percent of auxiliary materials.
2. The composition according to claim 1, wherein the composition comprises the following components in the following proportions by weight:
30 to 50 percent of ampelopsis grossedentata leaves, 1 to 10 percent of hovenia dulcis thunb,
1 to 5 percent of dark plum fruit, 1 to 5 percent of boat-fruited sterculia seed,
0.1 to 0.5 percent of vitamin C and 35 to 50 percent of auxiliary materials.
3. The composition according to claim 2, wherein the composition comprises the following components in the following proportions by weight:
50 percent of ampelopsis grossedentata leaves, 5 percent of hovenia dulcis thunb,
2 percent of dark plum fruit, 2 percent of boat-fruited sterculia seed,
0.15 percent of vitamin C and 40.85 percent of auxiliary material.
4. The composition as claimed in claim 1 to 3, wherein the composition comprises processed powdered extracts of Ampelopsis grossedentata leaf, Hovenia dulcis seed, Prunus mume and Sterculia Lychophora.
5. The composition according to claims 1-3, wherein the auxiliary materials in the composition are selected from one or more of lactose, microcrystalline cellulose, maltodextrin, isomaltooligosaccharide, fruit and vegetable powder, concentrated fruit and vegetable juice, magnesium stearate, silicon dioxide, titanium dioxide, beeswax, purified water, sucralose, edible salt, essence, pigment, glycerol, povidone K30 and gelatin.
6. A preparation method of the composition as claimed in claims 1 to 3, wherein the method comprises the step of mixing Ampelopsis grossedentata leaves, Hovenia dulcis Thunb, Prunus mume, Sterculia lychnophora, vitamin C according to the compatibility ratio.
7. The method of claim 6, wherein the Ampelopsis grossedentata leaves, Hovenia dulcis seeds, Prunus mume, and Sterculia Lychophora are processed to obtain powdered extracts before mixing.
8. Use of the composition of claims 1-3 in the preparation of a functional food for alleviating hangover.
9. Use of a composition according to claims 1 to 3 for the preparation of a medicament for the prevention of acute and/or chronic alcoholism.
10. The use according to claim 9, wherein the composition is prepared as a powder, tablet, granule, capsule, soft capsule or oral liquid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011053587.4A CN112007092A (en) | 2020-09-29 | 2020-09-29 | Anti-alcohol composition and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011053587.4A CN112007092A (en) | 2020-09-29 | 2020-09-29 | Anti-alcohol composition and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112007092A true CN112007092A (en) | 2020-12-01 |
Family
ID=73527587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011053587.4A Pending CN112007092A (en) | 2020-09-29 | 2020-09-29 | Anti-alcohol composition and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112007092A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112691150A (en) * | 2021-01-28 | 2021-04-23 | 宁波玉健医药有限公司 | Composition and preparation method and application thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772586A (en) * | 2011-05-13 | 2012-11-14 | 贵州省生物研究所 | Preparation with hangover alleviating and liver protection functions and preparation method thereof |
CN102846771A (en) * | 2012-07-04 | 2013-01-02 | 贵州省生物研究所 | Composition with antialcoholism and hepatoprotective effect |
CN107007813A (en) * | 2017-05-27 | 2017-08-04 | 云南德彩堂生物医药科技有限公司 | A kind of efficient relieving alcoholism and protecting liver composition, its preparation method and application |
CN109674896A (en) * | 2019-01-23 | 2019-04-26 | 武汉藻优生物科技有限公司 | A kind of vine tea flavone extract and its preparation method and application |
CN111066994A (en) * | 2020-01-02 | 2020-04-28 | 广东轻工职业技术学院 | Functional beverage for dispelling effects of alcohol and protecting liver and preparation method thereof |
CN111184807A (en) * | 2018-11-14 | 2020-05-22 | 衡阳西汉至尊生物科技有限公司 | Traditional Chinese medicine composition for dispelling effects of alcohol and preparation method thereof |
CN111249371A (en) * | 2018-11-30 | 2020-06-09 | 内蒙古伊利实业集团股份有限公司 | Composition for dispelling effects of alcohol and protecting liver and product |
-
2020
- 2020-09-29 CN CN202011053587.4A patent/CN112007092A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772586A (en) * | 2011-05-13 | 2012-11-14 | 贵州省生物研究所 | Preparation with hangover alleviating and liver protection functions and preparation method thereof |
CN102846771A (en) * | 2012-07-04 | 2013-01-02 | 贵州省生物研究所 | Composition with antialcoholism and hepatoprotective effect |
CN107007813A (en) * | 2017-05-27 | 2017-08-04 | 云南德彩堂生物医药科技有限公司 | A kind of efficient relieving alcoholism and protecting liver composition, its preparation method and application |
CN111184807A (en) * | 2018-11-14 | 2020-05-22 | 衡阳西汉至尊生物科技有限公司 | Traditional Chinese medicine composition for dispelling effects of alcohol and preparation method thereof |
CN111249371A (en) * | 2018-11-30 | 2020-06-09 | 内蒙古伊利实业集团股份有限公司 | Composition for dispelling effects of alcohol and protecting liver and product |
CN109674896A (en) * | 2019-01-23 | 2019-04-26 | 武汉藻优生物科技有限公司 | A kind of vine tea flavone extract and its preparation method and application |
CN111066994A (en) * | 2020-01-02 | 2020-04-28 | 广东轻工职业技术学院 | Functional beverage for dispelling effects of alcohol and protecting liver and preparation method thereof |
Non-Patent Citations (3)
Title |
---|
刘建新,等: "瑶族藤茶对兔肠平滑肌的影响和解酒实验研究", 《中国民族医药杂志》 * |
吴晓冰,等主编: "《解酒醒酒与护肝养胃》", 31 August 2007, 金盾出版社 * |
谭胜蓝,等: "二氢杨梅素心血管保护作用的研究进展", 《中南药学》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112691150A (en) * | 2021-01-28 | 2021-04-23 | 宁波玉健医药有限公司 | Composition and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108434231B (en) | Medicinal and edible Chinese medicinal composition for resisting drunkenness and dispelling effects of alcohol and preparation method thereof | |
CN111671026A (en) | Turmeric composite alcohol-relieving and liver-protecting drink for relieving alcohol, dispelling effects of alcohol and protecting gastrointestinal tract and preparation method thereof | |
CN107050148B (en) | Traditional Chinese medicine composition for dispelling effects of alcohol and protecting liver and preparation method thereof | |
US20160199427A1 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
US10993468B2 (en) | Composition for relieving hangovers | |
CN113456725A (en) | Product for relieving alcoholism and preparation method thereof | |
CN111642614A (en) | Anti-alcohol tabletted candy and preparation method thereof | |
CN103999986B (en) | A kind of cold tea condensed juice and preparation method thereof | |
CN112007092A (en) | Anti-alcohol composition and preparation method thereof | |
JP3334725B2 (en) | Accelerator for reducing alcohol in the body, its metabolites and oral freshener | |
CN112618608A (en) | Composition with function of dispelling effects of alcohol and preparation method and application thereof | |
CN111870627A (en) | Sobering-up preparation and its preparing method and use | |
JPH10508880A (en) | Pharmaceutical composition for diabetes | |
CN111357891A (en) | Plant beverage containing artichoke and ginseng and preparation method thereof | |
JP4954552B2 (en) | Antiallergic agent | |
CN106727902B (en) | Cordyceps sinensis-containing traditional Chinese medicine composition for dispelling effects of alcohol and protecting liver and application thereof | |
KR101407889B1 (en) | Fraxinus rhynchophylla Hance extracts compositions for treating or preventing inflammatory diseases | |
CN114557411A (en) | Liver-protecting and alcoholism-relieving compound beverage and preparation method thereof | |
KR20190101063A (en) | Composition containing natural material extract for preventing and improving respiratory organ disease | |
CN113750149A (en) | Traditional Chinese medicine compound preparation for assisting in antioxidation | |
CN112106880A (en) | Hangover alleviating tabletting candy and preparation method thereof | |
CN112450396A (en) | Clausena lansium compound composition and preparation method and application thereof | |
CN107183426B (en) | Liver-protecting and alcohol-dispelling plant beverage, and preparation method and application thereof | |
KR101221623B1 (en) | Food Composition for Stress Relaxation, Fatigue Recovery or Athletic Performance Enhancement Comprising Extract of root of vitis | |
JP2004173589A (en) | Food for ameliorating or preventing pollinosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201201 |